H
HERON THERAPEUTI
NASDAQ: HRTX (Heron Therapeutics, Inc.)
Last update: yesterday, 9:17PM1.39
0.12 (9.45%)
| Previous Close | 1.27 |
| Open | 1.28 |
| Volume | 7,592,872 |
| Avg. Volume (3M) | 1,891,808 |
| Market Cap | 254,873,904 |
| Price / Sales | 1.26 |
| Price / Book | 32.37 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -5.24% |
| Operating Margin (TTM) | 8.11% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | 12.20% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -21.88 M |
| Levered Free Cash Flow (TTM) | -26.09 M |
| Return on Assets (TTM) | -0.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Heron Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.13 |
|
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.70% |
| % Held by Institutions | 82.47% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Clearline Capital Lp | 30 Sep 2025 | 9,712,527 |
| Palisade Capital Management, Lp | 30 Sep 2025 | 7,327,447 |
| Tejara Capital Ltd | 30 Sep 2025 | 4,589,715 |
| Jw Asset Management, Llc | 30 Sep 2025 | 3,292,633 |
| 52 Weeks Range | ||
| Median | 6.00 (331.66%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jan 2026 | 6.00 (331.65%) | Buy | 1.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jan 2026 | Announcement | Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth |
| 04 Dec 2025 | Announcement | Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) |
| 04 Nov 2025 | Announcement | Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress |
| 29 Oct 2025 | Announcement | Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors |
| 21 Oct 2025 | Announcement | Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |